Exelixis (0IJO) Share Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0IJO Analyst Ratings

Moderate Buy

9 Buy

4 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Exelixis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0IJO Stock 12 Month Forecast

Average Price Target

$43.60

▲(8.97% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $43.60 with a high forecast of $56.00 and a low forecast of $30.00. The average price target represents a 8.97% change from the last price of $40.01.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","33":"$33","41":"$41","49":"$49","57":"$57"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$56.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$43.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,33,41,49,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.357,42.483384615384615,43.60976923076923,44.73615384615385,45.86253846153846,46.98892307692308,48.115307692307695,49.241692307692304,50.36807692307693,51.494461538461536,52.62084615384616,53.74723076923077,54.873615384615384,{"y":56,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.357,41.52953846153846,41.70207692307692,41.87461538461538,42.04715384615385,42.219692307692306,42.39223076923077,42.56476923076923,42.737307692307695,42.90984615384615,43.08238461538462,43.25492307692308,43.42746153846154,{"y":43.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.357,40.483384615384615,39.60976923076923,38.73615384615385,37.86253846153846,36.98892307692308,36.115307692307695,35.241692307692304,34.36807692307692,33.494461538461536,32.62084615384615,31.747230769230768,30.873615384615384,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.065,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.68,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.114,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.78,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.729,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.772,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.357,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$56.00

Average Price Target$43.60

Lowest Price Target$30.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Derek Archila

Wells Fargo

$36→$30

Hold

-25.02%

Downside

Reiterated

10/21/25

Exelixis price target lowered to $30 from $36 at Wells FargoExelixis price target lowered to $30 from $36 at Wells Fargo

Andrew Berens

Leerink Partners

$38→$48

Buy

19.97%

Upside

Upgraded

10/21/25

Exelixis upgraded to Outperform from Market Perform at LeerinkExelixis upgraded to Outperform from Market Perform at Leerink

Sean Laaman

Morgan Stanley

$50→$44

Buy

9.97%

Upside

Reiterated

10/21/25

Exelixis's Zanza: A Strong Contender with Promising Survival Rates and Manageable Safety Profile

Leonid Timashev

RBC Capital

$45

Hold

12.47%

Upside

Reiterated

10/20/25

RBC Capital Reaffirms Their Hold Rating on Exelixis (EXEL)

Andy Hsieh

William Blair

―

Buy

―

Reiterated

10/20/25

Exelixis's Zanzalintinib Shows Promise in Phase III Trial, Justifying Buy Rating Despite Safety Concerns

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

10/20/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Alpha Cognition Inc (NASDAQ: ACOG) and Exelixis (NASDAQ: EXEL)

Paul Choi

Goldman Sachs

―

Buy

―

Reiterated

10/16/25

Goldman Sachs Reaffirms Their Buy Rating on Exelixis (EXEL)

Ashwani Verma

UBS

$35

Buy

-12.52%

Downside

Reiterated

10/15/25

Exelixis: Buy Rating Backed by Strategic Positioning and Growth Prospects

Jason Gerberry

Bank of America Securities

$45

Hold

12.47%

Upside

Reiterated

10/13/25

Exelixis Hold Rating: Modest Sales Forecasts and Competitive Challenges Amid Upcoming STELLAR-303 Data

Robert Burns

H.C. Wainwright

$46

Buy

14.97%

Upside

Reiterated

09/17/25

H.C. Wainwright Reaffirms Their Buy Rating on Exelixis (EXEL)

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$47

Buy

17.47%

Upside

Initiated

09/17/25

Exelixis (EXEL) Receives a New Rating from Roth MKM

Etzer Darout

Barclays

$40

Hold

-0.02%

Downside

Initiated

09/16/25

Exelixis (EXEL) Has a New Rating from Barclays

David Lebowitz

Citi

$56

Buy

39.97%

Upside

Reiterated

09/04/25

Exelixis's Promising Growth Potential and Strategic Expansion Justify Buy Rating

Yaron Werber

TD Cowen

$44

Buy

9.97%

Upside

Reiterated

07/29/25

TD Cowen Sticks to Their Buy Rating for Exelixis (EXEL)

Michael Schmidt

Guggenheim

$45

Buy

12.47%

Upside

Reiterated

07/29/25

Exelixis (EXEL) Gets a Buy from Guggenheim

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Derek Archila

Wells Fargo

$36→$30

Hold

-25.02%

Downside

Reiterated

10/21/25

Exelixis price target lowered to $30 from $36 at Wells FargoExelixis price target lowered to $30 from $36 at Wells Fargo

Andrew Berens

Leerink Partners

$38→$48

Buy

19.97%

Upside

Upgraded

10/21/25

Exelixis upgraded to Outperform from Market Perform at LeerinkExelixis upgraded to Outperform from Market Perform at Leerink

Sean Laaman

Morgan Stanley

$50→$44

Buy

9.97%

Upside

Reiterated

10/21/25

Exelixis's Zanza: A Strong Contender with Promising Survival Rates and Manageable Safety Profile

Leonid Timashev

RBC Capital

$45

Hold

12.47%

Upside

Reiterated

10/20/25

RBC Capital Reaffirms Their Hold Rating on Exelixis (EXEL)

Andy Hsieh

William Blair

―

Buy

―

Reiterated

10/20/25

Exelixis's Zanzalintinib Shows Promise in Phase III Trial, Justifying Buy Rating Despite Safety Concerns

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

10/20/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Alpha Cognition Inc (NASDAQ: ACOG) and Exelixis (NASDAQ: EXEL)

Paul Choi

Goldman Sachs

―

Buy

―

Reiterated

10/16/25

Goldman Sachs Reaffirms Their Buy Rating on Exelixis (EXEL)

Ashwani Verma

UBS

$35

Buy

-12.52%

Downside

Reiterated

10/15/25

Exelixis: Buy Rating Backed by Strategic Positioning and Growth Prospects

Jason Gerberry

Bank of America Securities

$45

Hold

12.47%

Upside

Reiterated

10/13/25

Exelixis Hold Rating: Modest Sales Forecasts and Competitive Challenges Amid Upcoming STELLAR-303 Data

Robert Burns

H.C. Wainwright

$46

Buy

14.97%

Upside

Reiterated

09/17/25

H.C. Wainwright Reaffirms Their Buy Rating on Exelixis (EXEL)

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$47

Buy

17.47%

Upside

Initiated

09/17/25

Exelixis (EXEL) Receives a New Rating from Roth MKM

Etzer Darout

Barclays

$40

Hold

-0.02%

Downside

Initiated

09/16/25

Exelixis (EXEL) Has a New Rating from Barclays

David Lebowitz

Citi

$56

Buy

39.97%

Upside

Reiterated

09/04/25

Exelixis's Promising Growth Potential and Strategic Expansion Justify Buy Rating

Yaron Werber

TD Cowen

$44

Buy

9.97%

Upside

Reiterated

07/29/25

TD Cowen Sticks to Their Buy Rating for Exelixis (EXEL)

Michael Schmidt

Guggenheim

$45

Buy

12.47%

Upside

Reiterated

07/29/25

Exelixis (EXEL) Gets a Buy from Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exelixis

1 Month

xxx

Success Rate

18/28 ratings generated profit

Average Return

+7.74%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +7.74% per trade.

3 Months

xxx

Success Rate

24/28 ratings generated profit

Average Return

+24.45%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +24.45% per trade.

1 Year

Yaron WerberTD Cowen

Success Rate

21/24 ratings generated profit

Average Return

+23.29%

reiterated a buy rating 3 months ago

Copying Yaron Werber's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +23.29% per trade.

2 Years

xxx

Success Rate

13/14 ratings generated profit

Average Return

+34.54%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 92.86% of your transactions generating a profit, with an average return of +34.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0IJO Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0IJO has received 19 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 0IJO average Analyst price target in the past 3 months is 43.60.

Each month's total comprises the sum of three months' worth of ratings.

0IJO Financial Forecast

0IJO Earnings Forecast

Next quarter’s earnings estimate for 0IJO is $0.69 with a range of $0.64 to $0.73. The previous quarter’s EPS was $0.75. 0IJO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 0IJO has Preformed in-line its overall industry.

0IJO Sales Forecast

Next quarter’s sales forecast for 0IJO is $590.00M with a range of $565.60M to $615.00M. The previous quarter’s sales results were $568.26M. 0IJO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0IJO has Preformed in-line its overall industry.

0IJO Stock Forecast FAQ

What is GB:0IJO’s average 12-month price target, according to analysts?

Based on analyst ratings, Exelixis’s 12-month average price target is 43.60.

What is GB:0IJO’s upside potential, based on the analysts’ average price target?

Exelixis has 8.97% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Exelixis a Buy, Sell or Hold?

Exelixis has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 4 hold ratings and 0 sell ratings.

What is Exelixis’s share price target?

The average share price target for Exelixis is 43.60. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $56.00 ,and the lowest forecast is $30.00. The average share price target represents 8.97% Increase from the current price of $40.01.

What do analysts say about Exelixis?

Exelixis’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Exelixis?

To buy shares of GB:0IJO, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Exelixis (0IJO) Share Forecast & Price Target

0IJO Analyst Ratings

0IJO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Exelixis

0IJO Analyst Recommendation Trends

0IJO Financial Forecast

0IJO Earnings Forecast

0IJO Sales Forecast

0IJO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts